Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Veronika Tóth
Our First Experiences With Brentuximab Vedotin in the Treatment of Cutaneous T-Cell Lymphoma
Bőrgyógyászati és Venerológiai Szemle
Meningovascular Neurosyphilis as the Cause of Ischemic Cerebrovascular Disease in a Young Man
Orvosi Hetilap
Medicine
Related publications
FDA Approval Summary: Brentuximab Vedotin in First‐Line Treatment of Peripheral T‐Cell Lymphoma
Oncologist
Cancer Research
Medicine
Oncology
Potentials of Brentuximab Vedotin in the Treatment of Relapse/Refractory Cutaneous T-Cell Lymphomas: Literature Review and Authors’ Observation
Vestnik dermatologii i venerologii
Successful Outcomes of Brentuximab Vedotin Therapy in Recurrent/Refractory Cutaneous T-Cell Lymphomas: Two Case Reports
Immunopathology, Allergology, Infectology
First Salvage Treatment With Bendamustine and Brentuximab Vedotin in Hodgkin Lymphoma: A Phase 2 Study of Fil Onlus
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Brentuximab Vedotin in Patients With Relapsed HIV-Related Lymphoma
Journal of the National Comprehensive Cancer Network : JNCCN
Medicine
Oncology
Patient-Reported Outcomes of Brentuximab Vedotin in Hodgkin Lymphoma and Anaplastic Large-Cell Lymphoma
OncoTargets and Therapy
Oncology
Pharmacology
Prognostic Factors in Patients With Relapsed or Refractory Systemic Anaplastic Large T-Cell Lymphoma (Alcl) Receiving Brentuximab Vedotin and Outcome After Treatment Failure.
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Treatment of Cutaneous T-Cell Lymphoma: An Update
Journal of the American Osteopathic Association, The
Medicine
Alternative Medicine
Complementary
Final Data From the Phase 3 Alcanza Study: Brentuximab Vedotin (Bv) vs Physician's Choice (Pc) in Patients (Pts) With Cd30-Positive (Cd30+) Cutaneous T-Cell Lymphoma (Ctcl)
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology